Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

278 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term survival after intensive chemotherapy or hypomethylating agents in AML patients aged 70 years and older: a large patient data set study from European registries.
Récher C, Röllig C, Bérard E, Bertoli S, Dumas PY, Tavitian S, Kramer M, Serve H, Bornhäuser M, Platzbecker U, Müller-Tidow C, Baldus CD, Martínez-Cuadrón D, Serrano J, Martínez-Sánchez P, Arbolí ER, Gil C, Bergua J, Bernal T, de la Fuente Burguera A, Delabesse E, Bidet A, Pigneux A, Montesinos P. Récher C, et al. Among authors: berard e. Leukemia. 2022 Apr;36(4):913-922. doi: 10.1038/s41375-021-01425-9. Epub 2021 Nov 13. Leukemia. 2022. PMID: 34775483 Free PMC article.
Improved outcome for AML patients over the years 2000-2014.
Bertoli S, Tavitian S, Huynh A, Borel C, Guenounou S, Luquet I, Delabesse E, Sarry A, Laurent G, Attal M, Huguet F, Bérard E, Récher C. Bertoli S, et al. Among authors: berard e. Blood Cancer J. 2017 Nov 29;7(12):635. doi: 10.1038/s41408-017-0011-1. Blood Cancer J. 2017. PMID: 29184070 Free PMC article.
Outcome of relapsed or refractory acute myeloid leukemia treated with intensive salvage chemotherapy in real life in comparison to intermediate dose cytarabine in phase 3 studies.
Bertoli S, Tavitian S, Berard E, Gadaud N, Luquet I, Huynh A, Sarry A, Huguet F, Récher C. Bertoli S, et al. Among authors: berard e. Leuk Lymphoma. 2019 Jan;60(1):238-241. doi: 10.1080/10428194.2018.1464156. Epub 2018 Jun 12. Leuk Lymphoma. 2019. PMID: 29893611 No abstract available.
Outcome of relapsed/refractory AML patients with IDH1R132 mutations in real life before the era of IDH1 inhibitors.
Largeaud L, Bertoli S, Bérard E, Dufrechou S, Prade N, Gadaud N, Tavitian S, Bories P, Luquet I, Sarry A, Mas V, Huguet F, Delabesse E, Récher C. Largeaud L, et al. Among authors: berard e. Leuk Lymphoma. 2020 Feb;61(2):473-476. doi: 10.1080/10428194.2019.1668937. Epub 2019 Sep 30. Leuk Lymphoma. 2020. PMID: 31566052 No abstract available.
More than ten percent of relapses occur after five years in AML patients with NPM1 mutation.
Bertoli S, Tavitian S, Bérard E, Mansat-De Mas V, Largeaud L, Gadaud N, Rieu JB, Vergez F, Luquet I, Huguet F, Sarry A, Delabesse E, Récher C. Bertoli S, et al. Among authors: berard e. Leuk Lymphoma. 2020 May;61(5):1226-1229. doi: 10.1080/10428194.2019.1706733. Epub 2020 Feb 5. Leuk Lymphoma. 2020. PMID: 32022605 No abstract available.
278 results